Global Bio Simulation Market Professional Survey Report 2019

2 Global Bio Simulation Quarterly Market Size Analysis

• 2.1 Bio Simulation Business Impact Assessment - COVID-19
  • 2.1.1 Global Bio Simulation Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
• 2.2 Global Bio Simulation Quarterly Market Size 2020-2021
• 2.3 COVID-19-Driven Market Dynamics and Factor Analysis
  • 2.3.1 Drivers
  • 2.3.2 Restraints
  • 2.3.3 Opportunities
  • 2.3.4 Challenges

3 Quarterly Competitive Assessment, 2020

• 3.1 By Players, Global Bio Simulation Quarterly Market Size, 2019 VS 2020
• 3.2 By Players, Bio Simulation Headquarters and Area Served
• 3.3 Date of Key Players Enter into Bio Simulation Market
• 3.4 Key Players Bio Simulation Product Offered
• 3.5 Mergers & Acquisitions, Expansion Plans

4 Impact of Covid-19 on Bio Simulation Segments, By Type

• 4.1 Introduction
  • 1.4.1 For Drug Development
  • 1.4.2 For Drug Discovery
  • 1.4.3 Other
• 4.2 By Type, Global Bio Simulation Market Size, 2019-2021

5 Impact of Covid-19 on Bio Simulation Segments, By Application

• 5.1 Overview
  • 5.5.1 Pharmaceutical and Biotechnology Companies
  • 5.5.2 Academic and Government Research Institutes
  • 5.5.3 Contract Research Organizations
  • 5.5.4 Regulatory Authorities
  • 5.5.5 Other End Users
• 5.2 By Application, Global Bio Simulation Market Size, 2019-2021
  • 5.2.1 By Application, Global Bio Simulation Market Size by Application, 2019-2021

6 Geographic Analysis

• 6.1 Introduction
• 6.2 North America
  • 6.2.1 Macroeconomic Indicators of US
  • 6.2.2 US
  • 6.2.3 Canada
• 6.3 Europe
  • 6.3.1 Macroeconomic Indicators of Europe
  • 6.3.2 Germany
  • 6.3.3 France
  • 6.3.4 UK
  • 6.3.5 Italy
• 6.4 Asia-Pacific
  • 6.4.1 Macroeconomic Indicators of Asia-Pacific
  • 6.4.2 China
  • 6.4.3 Japan
  • 6.4.4 South Korea
  • 6.4.5 India
  • 6.4.6 ASEAN
• 6.5 Rest of World
  • 6.5.1 Latin America
  • 6.5.2 Middle East and Africa

7 Company Profiles

• 7.1 Certara
  • 7.1.1 Certara Business Overview
  • 7.1.2 Certara Bio Simulation Quarterly Revenue, 2020
  • 7.1.3 Certara Bio Simulation Product Introduction
  • 7.1.4 Certara Response to COVID-19 and Related Developments
• 7.2 Simulation Plus
  • 7.2.1 Simulation Plus Business Overview
  • 7.2.2 Simulation Plus Bio Simulation Quarterly Revenue, 2020
  • 7.2.3 Simulation Plus Bio Simulation Product Introduction
  • 7.2.4 Simulation Plus Response to COVID-19 and Related Developments
• 7.3 Dassault Systèmes SA
  • 7.3.1 Dassault Systèmes SA Business Overview
  • 7.3.2 Dassault Systèmes SA Bio Simulation Quarterly Revenue, 2020
  • 7.3.3 Dassault Systèmes SA Bio Simulation Product Introduction
  • 7.3.4 Dassault Systèmes SA Response to COVID-19 and Related Developments
• 7.4 Medtronic
  • 7.4.1 Medtronic Business Overview
  • 7.4.2 Medtronic Bio Simulation Quarterly Revenue, 2020
  • 7.4.3 Medtronic Bio Simulation Product Introduction
  • 7.4.4 Medtronic Response to COVID-19 and Related Developments
• 7.5 Advanced Chemistry Development
  • 7.5.1 Advanced Chemistry Development Business Overview
  • 7.5.2 Advanced Chemistry Development Bio Simulation Quarterly Revenue, 2020
  • 7.5.3 Advanced Chemistry Development Bio Simulation Product Introduction
  • 7.5.4 Advanced Chemistry Development Response to COVID-19 and Related Developments
• 7.6 Chemical Computing Group
  • 7.6.1 Chemical Computing Group Business Overview
  • 7.6.2 Chemical Computing Group Bio Simulation Quarterly Revenue, 2020
  • 7.6.3 Chemical Computing Group Bio Simulation Product Introduction
  • 7.6.4 Chemical Computing Group Response to COVID-19 and Related Developments
• 7.7 Entelos Holding Corporation
  • 7.7.1 Entelos Holding Corporation Business Overview
  • 7.7.2 Entelos Holding Corporation Bio Simulation Quarterly Revenue, 2020
  • 7.7.3 Entelos Holding Corporation Bio Simulation Product Introduction
  • 7.7.4 Entelos Holding Corporation Response to COVID-19 and Related Developments
• 7.8 Genedata AG
  • 7.8.1 Genedata AG Business Overview
  • 7.8.2 Genedata AG Bio Simulation Quarterly Revenue, 2020
  • 7.8.3 Genedata AG Bio Simulation Product Introduction
  • 7.8.4 Genedata AG Response to COVID-19 and Related Developments
• 7.9 Physiomics PLC
  • 7.9.1 Physiomics PLC Business Overview
  • 7.9.2 Physiomics PLC Bio Simulation Quarterly Revenue, 2020
  • 7.9.3 Physiomics PLC Bio Simulation Product Introduction
  • 7.9.4 Physiomics PLC Response to COVID-19 and Related Developments
• 7.10 Rhenovia Pharma
  • 7.10.1 Rhenovia Pharma Business Overview
  • 7.10.2 Rhenovia Pharma Bio Simulation Quarterly Revenue, 2020
  • 7.10.3 Rhenovia Pharma Bio Simulation Product Introduction
  • 7.10.4 Rhenovia Pharma Response to COVID-19 and Related Developments

8 Key Findings

9 Appendix

• 9.1 About US